apoptosis protein arrays human phospho kinase (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems apoptosis protein arrays human phospho kinase

Figure 3: CUDC-101 inhibits ATC cell proliferation, and induces cell cycle arrest and <t>apoptosis.</t> (A) Basal expression of HDAC1, HDAC2 and EGFR in ATC cell lines. (B) Cell proliferation assay. Error bars are mean ± SD. (C) Cell cycle analysis after 24 hours of treatment. (D) The Caspase-Glo 3/7 assay after 48 hours of treatment with CUDC-101. *p < 0.05, **p < 0.01, ***p < 0.001. NS, no significant difference.

Apoptosis Protein Arrays Human Phospho Kinase, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 251 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho-protein+microarray+analysis/Proteome+Profiler+Human+Apoptosis+Array+Kit/pm25940539-166-2-39
Average 96 stars, based on 251 article reviews

apoptosis protein arrays human phospho kinase - by Bioz Stars, 2026-10

96/100 stars

Images

1) Product Images from "Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer."

Article Title: Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.

Journal: Oncotarget

doi: 10.18632/oncotarget.3268

Figure 3: CUDC-101 inhibits ATC cell proliferation, and induces cell cycle arrest and apoptosis. (A) Basal expression of HDAC1, HDAC2 and EGFR in ATC cell lines. (B) Cell proliferation assay. Error bars are mean ± SD. (C) Cell cycle analysis after 24 hours of treatment. (D) The Caspase-Glo 3/7 assay after 48 hours of treatment with CUDC-101. *p < 0.05, **p < 0.01, ***p < 0.001. NS, no significant difference.

Figure Legend Snippet: Figure 3: CUDC-101 inhibits ATC cell proliferation, and induces cell cycle arrest and apoptosis. (A) Basal expression of HDAC1, HDAC2 and EGFR in ATC cell lines. (B) Cell proliferation assay. Error bars are mean ± SD. (C) Cell cycle analysis after 24 hours of treatment. (D) The Caspase-Glo 3/7 assay after 48 hours of treatment with CUDC-101. *p < 0.05, **p < 0.01, ***p < 0.001. NS, no significant difference.

Techniques Used: Expressing, Proliferation Assay, Cell Cycle Assay, Caspase-Glo Assay

Figure 5: Protein targets of CUDC-101 in ATC cells. (A) CUDC-101 inhibits HDACs and MAPK in ATC cells. (B) Targets of CUDC-101 identified by phospho-kinase array. Phospho-kinase arrays were performed using cell lysates treated with and without CUDC-101. Shown are those proteins that were altered with CUDC-101 treatment in both ATC cell lines with > 1.5-fold difference. (C) Differentially expressed apoptotic proteins with and without CUDC-101 treatment. Apoptosis arrays were performed. Shown are those proteins that were altered with CUDC-101 treatment in both ATC cell lines with > 1.5-fold difference. For A–C, ATC cells were treated with the vehicle or CUDC-101 at 1.1 μM for 24 hours. (D) CUDC-101 reduces the expression of survivin, XIAP, and β-catenin. Cells were treated with the vehicle or CUDC-101 for 24 hours.

Figure Legend Snippet: Figure 5: Protein targets of CUDC-101 in ATC cells. (A) CUDC-101 inhibits HDACs and MAPK in ATC cells. (B) Targets of CUDC-101 identified by phospho-kinase array. Phospho-kinase arrays were performed using cell lysates treated with and without CUDC-101. Shown are those proteins that were altered with CUDC-101 treatment in both ATC cell lines with > 1.5-fold difference. (C) Differentially expressed apoptotic proteins with and without CUDC-101 treatment. Apoptosis arrays were performed. Shown are those proteins that were altered with CUDC-101 treatment in both ATC cell lines with > 1.5-fold difference. For A–C, ATC cells were treated with the vehicle or CUDC-101 at 1.1 μM for 24 hours. (D) CUDC-101 reduces the expression of survivin, XIAP, and β-catenin. Cells were treated with the vehicle or CUDC-101 for 24 hours.

Techniques Used: Expressing

Expressing:

Article Title: Enhanced Payload Release Enables Disitamab Vedotin to Surpass Trastuzumab Emtansine and Retain Efficacy in Acquired Resistance to Clinical Anti-HER2 Therapies
Article Snippet: After incubation, samples (50,000 cells) were acquired in an Accuri C6 Flow Cytometer (BD Biosciences), considering viable if they were negative for both Annexin V, which detects early apoptotic cells, and PI, which identifies necrotic cells. .. To analyze the expression profiles of apoptosis-related proteins, the Proteome Profiler Human Apoptosis Array Kit (R&D Systems, Minneapolis, USA) was used according to the manufacturer’s instructions. ..

Article Title: Erica spiculifolia Extract Potentiates Cisplatin Cytotoxicity by Reactivating p53 and Caspase-3-Dependent Apoptosis in Colorectal Carcinoma.
Article Snippet: .. Protein expression profiling was carried out using membrane-based sandwich immunoassays according to the manufacturer’s instructions (Human Apoptosis Array Kit, ARY009; R&D Systems, Minneapolis, MN, USA). .. Signal intensities of individual protein spots were quantified by densitometric analysis using ImageJ software (version 1.8.0) and subsequently converted into absolute protein expression values.

Article Title: Erica spiculifolia Extract Potentiates Cisplatin Cytotoxicity by Reactivating p53 and Caspase-3-Dependent Apoptosis in Colorectal Carcinoma
Article Snippet: .. Protein expression profiling was carried out using membrane-based sandwich immunoassays according to the manufacturer’s instructions (Human Apoptosis Array Kit, ARY009; R&D Systems, Minneapolis, MN, USA). .. Signal intensities of individual protein spots were quantified by densitometric analysis using ImageJ software (version 1.8.0) and subsequently converted into absolute protein expression values.

Article Title: Enhanced Payload Release Enables Disitamab Vedotin to Surpass Trastuzumab Emtansine and Retain Efficacy in Acquired Resistance to Clinical Anti-HER2 Therapies.
Article Snippet: After incubation, samples (50,000 cells) were acquired in an Accuri C6 Flow Cytometer (BD Biosciences), considering viable if they were negative for both Annexin V, which detects early apoptotic cells, and PI, which identifies necrotic cells. .. To analyze the expression profiles of apoptosis-related proteins, the Proteome Profiler Human Apoptosis Array Kit (R&D Systems, Minneapolis, USA) was used according to the manufacturer’s instructions. ..

Membrane:

Imaging:

Article Title: Functionalized nanoparticle transforms “cold” to “hot” adenoid cystic carcinoma of salivary gland tumour microenvironment in vitro
Article Snippet: .. Upon following manufacturer instruction of Proteome Profiler Human Apoptosis Array Kit (R&D Systems, Cat RDSARY009), high-resolution images were acquired using Chemidoc MP imaging system and processed using Image Lab version 6.0 (Bio-Rad Laboratories, Hercules, CA, USA). .. Quantification of relative protein expressions were done using microarray profile plugin in ImageJ (ImageJ 1.52a, National Institutes of Health, USA).

other:

Article Title: Marine trichodermamide B inhibits prostate cancer progression via catalase inhibition-induced apoptosis
Article Snippet: After treatment with either DMSO (0.1%, v/v) or TRH2 (8 μM) for 48 h, cells were harvested and proteins were extracted and analyzed according to the instructions of the Human Apoptosis Array Kit (Cat# ARY009, R&D Systems).

Article Title: Marine trichodermamide B inhibits prostate cancer progression via catalase inhibition-induced apoptosis.
Article Snippet: Apoptosis and cell cycle distribution were analyzed by flow cytometry (NovoCyte, Agilent) as previously described (Gan et al., 2024).

Lysis:

Article Title: Functionalized nanoparticle transforms “cold” to “hot” adenoid cystic carcinoma of salivary gland tumour microenvironment in vitro
Article Snippet: .. The adenoid cystic carcinoma cells were added to 100 μL of lysis solution, supplied in Proteome Profiler Human Apoptosis Array Kit (R&D Systems, Cat RDSARY009) and 10 μL of protease inhibitor (Protease Inhibitor Cocktail I, Tocris, Cat 5500). ..

Protease Inhibitor: